Med24
clinical-research 19. 10. 2026 • 2 min read • ClinicalTrials.gov (Vanderbilt University Medical Center)

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

This study will assess the relationship between early unmet needs after hospital discharge and subsequent clinical outcomes among survivors of acute respiratory failure. The investigators hypothesize that early unmet needs are associated with poor outcomes at three months.

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

This study, identified by Clinical Trial ID NCT03738774, investigates the relationship between unmet needs following intensive care and subsequent clinical outcomes among survivors of acute respiratory failure. The research focuses on Post-Intensive Care Syndrome (PICS) and aims to determine if early unmet needs are associated with poorer outcomes at three months.

Study Design and Participant Characteristics

The study enrolls 200 participants who were diagnosed with acute respiratory failure during an ICU admission and discharged alive. Medical records will be reviewed to gather demographic and medical information, alongside data on comorbidities, medications, physical functioning, quality of life, substance use, social support, and healthcare utilization prior to and during ICU admission. Data regarding mechanical ventilation, arterial blood gas values, ARDS diagnosis, delirium, and overall medical status will be collected during the ICU stay.

Sponsored content

Post-Discharge Assessment and Follow-up

Post-discharge, the study will assess the participants’ needs, including prescriptions for oxygen or equipment, coordination with government assistance, physical or occupational therapy, medication adjustments, and referrals for home care services, dialysis, or counseling. Follow-up evaluations will occur at 1-4 weeks, 3 months, and 6 months following discharge. At 1-4 weeks, phone calls will assess whether post-discharge needs are met. At 3 months and 6 months, standardized surveys will evaluate mortality status, readmission rates, healthcare utilization, functional outcomes, quality of life, mental health status, coping mechanisms, and return to work. PICS will be a key outcome measure.

Original Scientific Source
ClinicalTrials.gov (Vanderbilt University Medical Center)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation
clinical-research

Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation

The purpose of this study is to demonstrate the non-inferiority of the Equinox System with respect to iLux 2020. Approximately 120 participants are expected to take part in the research trial at a minimum of three (3) and up to five (5) sites across the United States. The expected duration of the study will be six (6)...

16. 11. 2026 Read article →
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C
clinical-research

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

16. 11. 2026 Read article →
Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity
clinical-research

Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity

Post-stroke upper limb spasticity is an important condition that negatively affects motor recovery, upper limb functions, and activities of daily living. Multimodal treatment approaches are recommended in the management of spasticity. In recent years, the effects of transcranial magnetic stimulation (TMS) on upper...

10. 11. 2026 Read article →
A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
clinical-research

A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells,...

10. 11. 2026 Read article →
Advertisement